CAJ | 학술논문

目的评估利伐沙班在预防高原红细胞增多症(HAPC)患者全膝关节置换(TKR)术后深静脉血栓(DVT)形成中的作用.方法 2009年9月至2010年12月61例HAPC患者接受单侧TKR治疗,按随机数字表法将患者分为利伐沙班组和依诺肝素组.其中利伐沙班组共31例,平均年龄(62.8±9.2)岁,男11例,女20例；依诺肝素组30例,平均年龄(63.4±10.5)岁,男9例,女21例.术后8h分别采用利伐沙班和依诺肝素进行预防血栓发生治疗,共10 d.结果利伐沙班组31例中4例发生DVT,发生率为12.9％；依诺肝素组30例中7例发生DVT,发生率为23.3％,两组间无统计学差异(X2=1.122,P =0.289 ＞0.05).结论利伐沙班可有效预防HAPC患者TKR术后DVT形成,且安全、方便、作用持久.
목적 평고리벌사반재예방고원홍세포증다증(HAPC)환자전슬관절치환(TKR)술후심정맥혈전(DVT)형성중적작용.방법 2009년9월지2010년12월61례HAPC환자접수단측TKR치료,안수궤수자표법장환자분위리벌사반조화의낙간소조.기중리벌사반조공31례,평균년령(62.8±9.2)세,남11례,녀20례；의낙간소조30례,평균년령(63.4±10.5)세,남9례,녀21례.술후8h분별채용리벌사반화의낙간소진행예방혈전발생치료,공10 d.결과 리벌사반조31례중4례발생DVT,발생솔위12.9％；의낙간소조30례중7례발생DVT,발생솔위23.3％,량조간무통계학차이(X2=1.122,P =0.289 ＞0.05).결론 리벌사반가유효예방HAPC환자TKR술후DVT형성,차안전、방편、작용지구.
Objective To evaluate the prevention effect of rivaroxaban on deep venous thrombosis (DVT) after total knee replacement (TKR) in patients with high altitude polycythemia (HAPC).Methods 61 patients with HAPC who had TKR were followed up for the prevention effect of anticoagulant drugs on DVT.All patients were randomly divided into rivaroxaban group (31 patients,preventing DVT with rivaroxaban) and LMWH group (30 patients,preventing DVT with low molecular weight heparin).Both drugs were taken from eight hours to 10 days after TKR.Results The incidence of DVT in rivaroxaban group was 12.9％ (4/31),and it was 23.3％ (7/30) in LMWH group.Although the DVT incidence in LMWH group was higher than that in rivaroxaban group,there was no significant difference between them (X2 =1.122,P ＞ 0.05 ). Conclusions Rivaroxaban might be a safe and effective anticoagulant drug in preventing DVT after TKR in patients with high altitude polycythemia.